Genprex Strengthens Diabetes Gene Therapy Program with License of Additional Technology from University of Pittsburgh – Yahoo Finance

Technology for modulating autoimmunity expands intellectual property portfolio
AUSTIN, Texas , Dec. 15, 2022 /PRNewswire/ — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has entered into an exclusive license agreement (the Agreement) with
the University of Pittsburgh, granting Genprex a worldwide, exclusive license to certain patent applications and related technology and a worldwide, non-exclusive license to use certain related know-how, all related to modulating autoimmunity in Type 1 diabetes by using gene therapy. The preclinical technology transforms macrophages enabling them to reduce autoimmune activity in Type 1 diabetes and could be complementary to the Company’s existing diabetes technology.
“Gaining exclusive access to technology that modulates the immune system by transforming macrophages could prove to be significant to our broader research partnership with the laboratory of George Gittes, MD, Professor of Surgery and Pediatrics and Chief of the Division of Pediatric Surgery at the University of Pittsburgh School of Medicine,” said Mark Berger, MD, Chief Medical Officer of Genprex. “We are making significant strides in our program with Dr. Gittes’s innovative approach to treating diabetes by the transformation of alpha cells into beta-like cells and are excited to add to our arsenal this additional technology also out of Dr. Gittes’s lab, in collaboration with the laboratory of Dr. Xangwei Xiao, Assistant Professor of Surgery, also in the Division of Pediatric Surgery at the University of Pittsburgh’s School of Medicine. Not only could this new approach be used to reduce autoimmune activity in Type 1 diabetes by modulating the immune system but potentially it could also work in conjunction with the technology we have licensed previously.”
“With diabetes reaching epidemic proportions around the world, the work Dr. Gittes is pursuing in diabetes is absolutely critical. In the U.S. alone, there are more than 37 million people with diabetes (approximately 1.9 million of whom have Type 1 diabetes) and another approximately 96 million Americans who are pre-diabetic, or have abnormally elevated blood sugar levels. The opportunity to change the course of this disease with gene therapy is extremely compelling, and increasing our exclusive access to intellectual property could prove to be pivotal to our pathway forward,” said Rodney Varner, President and Chief Executive Officer of Genprex.
The Company signed an exclusive license agreement with the University of Pittsburgh in 2020. The gene therapy approach under the original license is comprised of a novel infusion process that uses an endoscope and an adeno-associated virus (AAV) vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, these genes express proteins that transform alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body’s immune system. In Type 2 diabetes, where autoimmunity is not at play, it is believed that exhausted beta cells will be rejuvenated and replenished.
This gene therapy approach was developed by Dr. Gittes. His preclinical research in this area has been published in peer-reviewed scientific publications, and he is the recipient of several research grants, including a $2.59 million grant awarded by the National Institutes of Health (NIH) National Institute of Diabetes and Digestive and Kidney Diseases.
Earlier studies in diabetic mouse models showed that the gene therapy restored normal blood glucose levels for an extended period of time, typically around four months. It is believed that the duration of restored blood glucose levels in mice could translate to decades in humans. Preliminary data from a more recent study in a non-human primate model of Type 1 diabetes also have been promising. Data from this study are expected to be presented at a scientific meeting during the first quarter of 2023.
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex’s oncology program utilizes its proprietary, non-viral ONCOPREX® Nanoparticle Delivery System, which the Company believes is the first systemic gene therapy delivery platform used for cancer in humans. ONCOPREX encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is administered intravenously, where it is then taken up by tumor cells that express tumor suppressor proteins that are deficient in the body. The Company’s lead product candidate, REQORSA™ (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC) (with each of these clinical programs receiving a Fast Track Designation from the Food and Drug Administration) and for small cell lung cancer. Genprex’s diabetes gene therapy approach is comprised of a novel infusion process that uses an endoscope and an adeno-associated virus (AAV) vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, the genes express proteins that transform alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body’s immune system. In Type 2 diabetes, where autoimmunity is not at play, it is believed that exhausted beta cells are also rejuvenated and replenished.
For more information, please visit the Company’s web site at www.genprex.com or follow Genprex on Twitter, Facebook and LinkedIn.
Cautionary Language Concerning Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex’s reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under “Item 1A – Risk Factors” in Genprex’s Annual Report on Form 10-K for the year ended December 31, 2021.
Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: the timing and success of Genprex’s clinical trials and regulatory approvals, including the extent and impact of the COVID-19 pandemic; the effect of Genprex’s product candidates, alone and in combination with other therapies, on cancer and diabetes; Genprex’s future growth and financial status; Genprex’s commercial and strategic partnerships, including those with its third party manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex’s intellectual property and licenses.
These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.
Genprex, Inc.
(877) 774-GNPX (4679)
GNPX Investor Relations
investors@genprex.com
GNPX Media Contact
Kalyn Dabbs
media@genprex.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/genprex-strengthens-diabetes-gene-therapy-program-with-license-of-additional-technology-from-university-of-pittsburgh-301703613.html
SOURCE Genprex, Inc.
Related Quotes
The performance at Xenetic Biosciences, Inc. ( NASDAQ:XBIO ) has been rather lacklustre of late and shareholders may be…
Yahoo Finance senior health reporter Anjalee Khemlani explains why Exact Sciences is pulling away from its competitor Guardant Health in its colorectal cancer test.
Yahoo Finance’s Anjalee Khemlani joins the Live show to discuss China’s reopening challenges as COVID cases rise as well as the latest surrounding Pfizer and BioNTech’s combined COVID and flu vaccine.
Two drug developers stand out as plain-as-day bargains in the new year, while another top-performing biotech stock looks poised to disappoint.
Guardant unveiled results for its colon cancer-detecting blood test that lagged rival Exact. GH stock crashed as EXAS stock jumped Friday.
As of Thursday afternoon, they were still up more than 10% for the week, according to data from S&P Global Intelligence. On Tuesday, the company disclosed in a filing that Puma CEO Allan Auerbach bought 568,181 shares of Puma stock for roughly $2.5 million dollars and now owns 20% of the company. The choice was seen as a sign Auerbach has faith in the company's pipeline beyond its only marketed product, Nerlynx, used to treat HER2-positive breast cancer, a type of breast cancer that utilizes a protein called human epidermal growth factor receptor 2 (HER2).
(Bloomberg) — Moderna Inc. investors may finally be ready to look beyond Covid, as promising data on a personalized cancer vaccine sparked hope for the biotechnology company’s broader pipeline amid the fading pandemic. Most Read from BloombergTrump Hawks Superhero NFT Trading Cards as Crypto Universe ImplodesWorld’s Largest Hotel Aquarium Bursts Spilling 1,500 FishCovid Unleashed in Beijing Shows Rest of China What’s NextNobel Prize-Winning Economics Professor Faces Harassment InquiryBinance, A
Axsome Therapeutics (NASDAQ: AXSM) has done something most other stocks haven't been able to do this year: It's beaten the bear market. The company acquired its first product from Jazz Pharmaceuticals this spring — sleep-disorder drug Sunosi. At Jazz, Sunosi sales soared 104% last year to $57.9 million.
“We just launched a rocket and got it to the moon,” said co-CEO Helmy Eltoukhy. “It's illogical, irrational, and people don't understand the science.”
BioCryst (BCRX) down as it drops the development of BCX9930, which was being evaluated for PNH.
Eating even small amounts of ultra-processed foods could significantly increase the risk of developing dementia, new study finds.
Now comes some fresh research from Rush University Medical Center in Chicago that is terrific news. A long-running and detailed study of nearly 1,000 elderly people has found that those who ate certain foods in their diet—those that contain certain natural compounds known as flavonols—were less likely to get dementia. “The highest quintile of flavonol intake…versus the lowest is associated with a 32% reduction in the rate of cognitive decline,” says Dr. Thomas Holland, an MD and professor at Rush Medical College, who led the study.
Recent results suggest the company's cancer vaccine candidate can succeed where others have failed.
Anavex Life Sciences Corp. (NASDAQ:AVXL) Q4 2022 Earnings Call Transcript November 28, 2022 Anavex Life Sciences Corp. misses on earnings expectations. Reported EPS is $-0.18 EPS, expectations were $-0.16. Clint Tomlinson: Welcome to the Anavex Life Sciences’ Fiscal 2022 Fourth Quarter Conference Call. My name is Clint Tomlinson, and I’ll be your host for today’s […]
Pfizer (NYSE: PFE) and AbbVie (NYSE: ABBV) have produced strong total returns over the past decade, and both pharmaceutical companies have what it takes to keep up the pace going forward, despite looming patent cliffs for both. Over the past five years, AbbVie's total return is 249%, and Pfizer's is 167%, and given their strong cash flow and ability to purchase assets and develop their own therapies with large pipelines, there are plenty of reasons to see the two dividend stocks doubling your return over the next decade. Pfizer is off to a record year, with management saying in its third-quarter earnings report that it expects annual revenue between $99.5 billion to $102 billion, which at the midpoint represents a rise of 23.9% over 2021.
Peachtree City police arrested two convenience store employees for selling an illegal, controlled substance over-the-counter.
Canadian singer Celine Dion recently announced she is suffering from Stiff-Person Syndrome, inspiring claims on social media that her diagnosis is linked to Covid-19 vaccination. This is unproven; experts say there is no evidence the shots cause the rare neurological condition, and a Pfizer document purported to show a connection was misrepresented."In Pfizer's own document. Trying to knock down the population…. Well they are doing it. Someone tell Celine Dion because you know the doctors will d
The transaction will present a test case for Oregon's new oversight law for mergers and acquisitions.
LOL, this is probably a really weird announcement to any family member I haven't told.View Entire Post ›
Nearly 8,900 more people have died of cancer than expected in Britain since the start of the pandemic, amid calls for the Government to appoint a minister to deal with the growing crisis.

source